Silhouette

Silhouette Therapeutics was a biotechnology company focused on developing innovative gene therapies for the treatment of chronic retinal diseases. The company specialized in utilizing adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to the eye, aiming to provide long-term, sustainable treatment options for conditions such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Founded by leading experts in ophthalmology from institutions like Johns Hopkins University, Silhouette's technology was designed to overcome the burden of frequent intravitreal injections. The company was acquired by Gyroscope Therapeutics in 2019 to strengthen their pipeline of ocular gene therapy programs, which was subsequently integrated into Novartis following its acquisition of Gyroscope.